RHHBY Roche Holding AG Loading...

From PFE earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
14:00
May 05 ◎
Chris Bosso EVP & Chief Business Officer, R&D, Pfizer, Inc. PFE Q1 FY26 call
Pfizer's PD-1/VEGF bispecific (4404) competes with Roche's bevacizumab-based therapies, claiming higher VEGFA affinity.
RHHBY
LOW

About RHHBY Analyst Coverage

Buzzberg tracks RHHBY (Roche Holding AG) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Chris Bosso.